We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Eisai Company Ltd (PK) | USOTC:ESALY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.51 | 61.51 | 61.86 | 0.00 | 01:00:00 |
From Jun 2022 to Jun 2024
10:31 a.m. ET -- Biogen Inc. and Eisai Co. are two of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The U.S. Food and Drug Administration on Friday granted conditional approval to the companies' lecanemab, the most promising drug to date in a new class of medicines that may help slow cognitive decline caused by Alzheimer's disease. Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com).
(END) Dow Jones Newswires
January 09, 2023 10:46 ET (15:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Eisai (PK) Chart |
1 Month Eisai (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
